Perampanel

Mechanism

Chemical and Commercial Profile

Common trade names: Fycompa.
Group: Third generation antiepileptic, derived from pyridone.

Mechanism of Action

Perampanel acts through **selective and non-competitive antagonism of AMPA-type glutamate receptors** (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate) located in the neuronal postsynaptic membranes of the cortex and hippocampus. By binding to a specific allosteric site in the ion channel, it blocks the massive influx of sodium and calcium in response to presynaptic glutamate release, potently suppressing the propagation of depolarizing currents from the epileptogenic focus.

Pharmacokinetics

Pharmacokinetics

• Absorption: Rapid and complete orally; 100% bioavailability. It is not altered by food. The plasma peak is reached 2-3 hours after taking.
• Distribution: Very high binding to plasma proteins (>95%), mainly to serum albumin. The volume of distribution is 1.1 L/kg. It easily crosses the blood-brain barrier.
• Metabolism: Hepatic oxidative catalyzed mainly by the isoenzyme CYP3A4 (70%) and CYP3A5, generating multiple inactive metabolites.
• Excretion: Fecal (>70%) and renal (22%) mainly in the form of inactive demethylated metabolites.
• Half-life (t_1/2): Extremely long: 105 hours in healthy adults. It allows a stable state of balance and reduces the immediate clinical impact of therapeutic forgetfulness.

Indicators and dose

Indications

• Adjuvant therapy in focal seizures (with or without secondary generalization) from 12 years of age.
• Adjuvant therapy in primary generalized tonic-clonic seizures in patients diagnosed with idiopathic generalized epilepsy.

Dosage and Settings

• Standard Qualification Guidelines (Adults):
  • Weeks 1 and 2: 2 mg once daily in the evening.
  • Weeks 3 and 4: 4 mg once daily in the evening.
  • Subsequent weeks: Increase by 2 mg every two weeks to a maximum of 12 mg/day.
• Common therapeutic range: 4-8 mg/day (in focal crises); 8-12 mg/day (in tonic-clonic seizures).
• Kidney Failure: Not recommended in patients with creatinine clearance Cl_Cr < 30 ml/min or on hemodialysis due to lack of data.
• Liver Failure: Decrease the initial dose by 50% and limit the maximum maintenance dose to 6 mg/day (in Child-Pugh A) or 4 mg/day (in Child-Pugh B). Contraindicated in Child-Pugh C.

Security

Contraindications

• Hypersensitivity to the active ingredient or excipients.
• Presence of previous severe unstable psychiatric disorders (such as schizophrenia or history of violence).

Adverse Effects (ADR)

Black Safety Alert · Risk of Homicidal Behavior

Perampanel carries a black box FDA safety warning due to the elevated risk of inducing **severe neuropsychiatric reactions involving suicidal ideation, extreme hostility, homicidal ideation, and actual violent or homicidal behavior**. These effects are dependent on the dose and titration rate. It requires continuous monitoring of behavior and discontinuing the drug immediately if extreme aggressiveness is observed.

• Neurological: Severe postural dizziness, drowsiness, chronic fatigue, motor ataxia with symmetrical gait instability (very common), early-onset transient dysarthria.
• Metabolic: Moderate increase in appetite, weight gain (moderate), nausea of central origin.

Clinical Interactions

• With CYP3A4 Inducers: Carbamazepine, phenytoin and phenobarbital massively reduce serum levels of perampanel by 50-70% by inducing its hepatic clearance, requiring doubling the maximum dose of perampanel.
• Effect on Contraceptives: At doses higher than 12 mg/day, perampanel markedly reduces the effectiveness of oral contraceptives containing estrogens.

Pregnancy and Breastfeeding

FDA Category: C. Very limited human data; Animal pregnancy models do not report direct bone teratogenicity, but they associate long-term embryo-fetal toxicity. Avoid in pregnant women. Breastfeeding: Relatively contraindicated; It is excreted in milk, reaching considerable concentrations in the infant. Monitor lethargy.